MedPath
Found 6 clinical trials|View Analysis
Sort by:

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3
Not yet recruiting
Conditions
Nasopharyngeal Carcinoma
Interventions
First Posted Date
2024-10-07
Last Posted Date
2024-10-07
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
400
Registration Number
NCT06629597
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Phase 3
Not yet recruiting
Conditions
Small Cell Lung Cancer
Interventions
First Posted Date
2024-09-25
Last Posted Date
2024-11-15
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
438
Registration Number
NCT06612151
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Phase 1 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: YL201
First Posted Date
2024-05-01
Last Posted Date
2024-12-06
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
162
Registration Number
NCT06394414
Locations
🇨🇳

Linyi Central Hospital, Linyi, Shandong, China

🇨🇳

Zaozhuang Municipal Hospital, Zaozhuang, Shandong, China

🇨🇳

West China Hospital, Sichuan University, Sichuan, Sichuan, China

and more 27 locations

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Phase 2
Recruiting
Conditions
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
Drug: YL201 for Injection
First Posted Date
2024-02-05
Last Posted Date
2024-10-16
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
100
Registration Number
NCT06241846
Locations
🇨🇳

Peking University First Hospital, Peking, Beijing, China

🇨🇳

Peking University Third Hospital, Peking, Beijing, China

🇨🇳

Hunan Cancer Hospital, Hunan, Changsha, China

and more 21 locations

A Study YL201 in Patients With Selected Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Interventions
Drug: YL201 for Injection
First Posted Date
2023-09-28
Last Posted Date
2023-12-20
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
640
Registration Number
NCT06057922
Locations
🇨🇳

Jiangmen Central Hospital, Jiangmen, Guangdong, China

🇨🇳

Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China

🇨🇳

Fujian Cancer Hospital, Fuzhou, Fujian, China

and more 52 locations

A Study of YL201 in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Interventions
Drug: YL201
First Posted Date
2022-06-27
Last Posted Date
2024-12-04
Lead Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Target Recruit Count
196
Registration Number
NCT05434234
Locations
🇺🇸

University California San Diego Moores Cancer Center, La Jolla, California, United States

🇺🇸

Georgetown University Medical Center, Washington, District of Columbia, United States

🇺🇸

Community Health Network, Indianapolis, Indiana, United States

and more 40 locations
© Copyright 2025. All Rights Reserved by MedPath